Trial Profile
A Phase I, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Intravenous ETX2514 Administered in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Apr 2020
Price :
$35
*
At a glance
- Drugs Durlobactam (Primary) ; Durlobactam/sulbactam (Primary) ; Imipenem/cilastatin; Sulbactam
- Indications Acinetobacter infections
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Entasis Therapeutics
- 13 Apr 2020 Results published in the Antimicrobial Agents and Chemotherapy
- 09 Oct 2017 According to an Entasis Therapeutics media release, data were presented at IDWeek 2017.
- 08 Oct 2017 Results presented at the IDWeek 2017